High-Risk Metachronous Oligometastatic Prostate Cancer Trial

High-Risk Metachronous Oligometastatic Prostate Cancer Trial
Conditions: Prostate Cancer; Oligometastatic Disease

Interventions: Drug: niraparib/abiraterone acetate; Radiation: Stereotactic ablative radiation therapy (SABR); Drug: Androgen deprivation therapy (ADT)

Sponsors: University of Maryland, Baltimore; Janssen Scientific Affairs, LLC

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 22, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments